Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Linda Fabris, Warren Fiskus, Kavi O'Connor, Zachary Zaroogian, Shishir Waghray, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Lucia Masarova, Taghi Manshouri, Kapil Bhalla, Claes Wahlestedt, Ross Levine, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2025-3759

Published: 2025

Journal Articles

RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977.

Annabelle Anandappa, Vidushi Trivedi, Megan Bones, Jahnavi Raval, Rachel Hefner, Ashley Wooten, Robert Bowman, Ross Levine, Daniel Starczynowski, Linde Miles

Blood (2025) 146 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2025-3229

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Blood (2025) 146 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2025-3432

Published: 2025

Journal Articles

A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies

Charyguly Annageldiyev, Upendar Golla, Satyam Patel, Rebecca Gelfer, Joseph Cioccio, Kentaro Minagawa, Hong Zheng, Su-Fern Tan, David Feith, Thomas Loughran, Ross Levine, Arati Sharma, David Claxton

Blood (2025) 146 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2025-3488

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Integrating single-cell whole genome and transcriptome sequencing to track the clonal evolution of TP53-mutated myeloid neoplasms

Sarun Sereewattanawoot, Maria Sirenko, Georgios Asimomitis, Sheng Cai, Shoron Mowla, Kaitlyn Ko, Francesco Maura, Ross Levine, Sohrab Shah, Andrew McPherson, Gunes Gundem, Elli Papaemmanuil

Blood (2025) 146 (Supplement 1): 5014.

https://doi.org/10.1182/blood-2025-5014

Published: 2025

Journal Articles

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Jan Philipp Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Giuliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Ross Levine, Prithviraj Bose, Raajit Rampal

Blood (2025) 146 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2025-3814

Published: 2025

Journal Articles

Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.

Blood (2025) 146 (Supplement 1): 5263.

https://doi.org/10.1182/blood-2025-5263

Published: 2025

Journal Articles

TP53 mutated clonal hematopoiesis patterns over serial follow up: A single center clinic experience

Tamanna Haque, Nicola Kim, Gabrielle Arauz, Dipti Gupta, Andriy Derkach, Brittany Reid, Farzeen Aslam, Angela Brannon, Kelly Bolton, Roni Tamari, Simon Mantha, Ross Levine

Blood (2025) 146 (Supplement 1): 6706.

https://doi.org/10.1182/blood-2025-6706

Published: 2025

Journal Articles

AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)

Marc Usart, Shivam Rai, Kavi O'Connor, Quentin Kimmerlin, Zachary Zaroogian, Matthew Wereski, Charlie Xu, Craig Masse, Stevan Hubbard, Ross Levine, Maria Kleppe, Radek Skoda, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2025-1983

Published: 2025

Journal Articles

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Blood (2025) 146 (Supplement 1): 220.

https://doi.org/10.1182/blood-2025-220

Published: 2025

Journal Articles

Codon-Specific Differences in RAS Mutations in AML and Differential Response to Therapeutic Agents

Annabelle J Anandappa, Vidushi Trivedi, Tiffany Merlinsky, Nicole Delgaudio, Emily Guzzardi, Ashley Wooten, Daniel Starczynowski, Robert L. Bowman, Ross Levine, Linde A. Miles

Blood (2024) 144 (Supplement 1): 2713.

https://doi.org/10.1182/blood-2024-205218

Published: 2024

Journal Articles

Leukemia secondary to myeloproliferative neoplasms

Andrew J. Dunbar, Raajit K. Rampal, Ross Levine

Blood (2020) 136 (1): 61–70.

https://doi.org/10.1182/blood.2019000943

Published: 2020

Journal Articles

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

Rupali Das, Peng Guan, Leslee Sprague, Katherine Verbist, Paige Tedrick, Qi Angel An, Cheng Cheng, Makoto Kurachi, Ross Levine, E. John Wherry, Scott W. Canna, Edward M. Behrens, Kim E. Nichols

Blood (2016) 127 (13): 1666–1675.

https://doi.org/10.1182/blood-2015-12-684399

Published: 2016

Includes: Supplemental data

Journal Articles

Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms

Edwin Chen, Rebekka K. Schneider, Lawrence J. Breyfogle, Emily A. Rosen, Luke Poveromo, Shannon Elf, Amy Ko, Kristina Brumme, Ross Levine, Benjamin L. Ebert, Ann Mullally

Blood (2015) 125 (2): 327–335.

https://doi.org/10.1182/blood-2014-04-567024

Published: 2015

Includes: Supplemental data

Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Blood (2013) 122 (11): 1923–1934.

https://doi.org/10.1182/blood-2013-03-492181

Published: 2013

Includes: Supplemental data

Journal Articles

Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML

Elspeth M. Payne, Niccolò Bolli, Jennifer Rhodes, Omar I. Abdel-Wahab, Ross Levine, Cyrus V. Hedvat, Richard Stone, Arati Khanna-Gupta, Hong Sun, John P. Kanki, Hanna T. Gazda, Alan H. Beggs, Finbarr E. Cotter, A. Thomas Look

Blood (2011) 118 (4): 903–915.

https://doi.org/10.1182/blood-2010-11-318022

Published: 2011

Includes: Multimedia, Supplemental data

Journal Articles

High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated with Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS)

Alfonso Quintás-Cardama, MD, Ross Levine, MD, Taghi Manshouri, Outi Kilpivaara, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2010) 116 (21): 461.

https://doi.org/10.1182/blood.V116.21.461.461

Published: 2010

Journal Articles

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Blood (2010) 116 (21): 851.

https://doi.org/10.1182/blood.V116.21.851.851

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977.

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Integrating single-cell whole genome and transcriptome sequencing to track the clonal evolution of TP53-mutated myeloid neoplasms

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.

TP53 mutated clonal hematopoiesis patterns over serial follow up: A single center clinic experience

AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Codon-Specific Differences in RAS Mutations in AML and Differential Response to Therapeutic Agents

Leukemia secondary to myeloproliferative neoplasms

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML

High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated with Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS)

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only